Pharming Group/$PHAR
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Pharming Group
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.
Ticker
$PHAR
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
404
ISIN
US71716E1055
Website
Pharming Group Metrics
BasicAdvanced
$697M
-
-$0.02
0.44
-
Price and volume
Market cap
$697M
Beta
0.44
52-week high
$12.61
52-week low
$7.50
Average daily volume
4K
Financial strength
Current ratio
2.761
Quick ratio
1.996
Long term debt to equity
51.259
Total debt to equity
55.341
Interest coverage (TTM)
1.10%
Profitability
EBITDA (TTM)
16.952
Gross margin (TTM)
88.98%
Net profit margin (TTM)
-4.40%
Operating margin (TTM)
4.20%
Effective tax rate (TTM)
-290.62%
Revenue per employee (TTM)
$790,000
Management effectiveness
Return on assets (TTM)
1.99%
Return on equity (TTM)
-6.78%
Valuation
Price to revenue (TTM)
21.694
Price to book
2.74
Price to tangible book (TTM)
7.79
Price to free cash flow (TTM)
1,369.736
Free cash flow yield (TTM)
0.07%
Free cash flow per share (TTM)
0.75%
Growth
Revenue change (TTM)
24.13%
Earnings per share change (TTM)
30.18%
3-year revenue growth (CAGR)
16.67%
10-year revenue growth (CAGR)
29.99%
3-year earnings per share growth (CAGR)
10.95%
10-year earnings per share growth (CAGR)
-0.95%
Bulls say / Bears say
Pharming Group's total revenues increased by 42% to US$79.1 million in Q1 2025, driven by a 49% rise in RUCONEST® sales, indicating strong market demand. (pharming.com)
The company raised its 2025 total revenue guidance to US$325 - US$340 million, reflecting confidence in sustained growth. (pharming.com)
Pharming completed the acquisition of Abliva AB, adding KL1333 for mitochondrial DNA-driven primary mitochondrial diseases to its pipeline, potentially expanding its market reach. (pharming.com)
The departure of CFO Jeroen Wakkerman at the end of May 2025 introduces potential leadership uncertainty during a critical growth phase. (pharming.com)
Despite revenue growth, Pharming reported an operating loss of US$7.0 million in Q1 2025, indicating ongoing profitability challenges. (pharming.com)
The acquisition of Abliva AB led to a significant cash position decline from US$169.4 million to US$108.9 million, which may impact financial flexibility. (pharming.com)
Data summarised monthly by Lightyear AI. Last updated on 11 Jul 2025.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Pharming Group stock?
Pharming Group (PHAR) has a market cap of $697M as of July 18, 2025.
What is the P/E ratio for Pharming Group stock?
The price to earnings (P/E) ratio for Pharming Group (PHAR) stock is 0 as of July 18, 2025.
Does Pharming Group stock pay dividends?
No, Pharming Group (PHAR) stock does not pay dividends to its shareholders as of July 18, 2025.
When is the next Pharming Group dividend payment date?
Pharming Group (PHAR) stock does not pay dividends to its shareholders.
What is the beta indicator for Pharming Group?
Pharming Group (PHAR) has a beta rating of 0.44. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.